The lack of more robust clinical activity in this study is, in part, in contrast to the recent role of MEK inhibitors in BRAFV600-mutant melanoma or selumetinib in neurofibromatosis type 1 inoperable plexiform tumors and may be attributed to several different factors [20]. Here, MAP2K7 is linked to neurofibromatosis type 1.